Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Invested Capital (2016 - 2025)

Aptevo Therapeutics' Invested Capital history spans 11 years, with the latest figure at $17.4 million for Q3 2025.

  • For Q3 2025, Invested Capital rose 293.48% year-over-year to $17.4 million; the TTM value through Sep 2025 reached $17.4 million, up 293.48%, while the annual FY2024 figure was $4.8 million, 61.09% down from the prior year.
  • Invested Capital for Q3 2025 was $17.4 million at Aptevo Therapeutics, up from $6.5 million in the prior quarter.
  • Across five years, Invested Capital topped out at $25.0 million in Q2 2022 and bottomed at -$3.9 million in Q1 2022.
  • The 5-year median for Invested Capital is $14.7 million (2023), against an average of $12.8 million.
  • The largest annual shift saw Invested Capital surged 738.28% in 2021 before it crashed 124.14% in 2025.
  • A 5-year view of Invested Capital shows it stood at $12.9 million in 2021, then skyrocketed by 55.04% to $20.0 million in 2022, then tumbled by 38.82% to $12.2 million in 2023, then plummeted by 61.09% to $4.8 million in 2024, then skyrocketed by 265.76% to $17.4 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Invested Capital are $17.4 million (Q3 2025), $6.5 million (Q2 2025), and -$1.5 million (Q1 2025).